Efficacy of acupuncture on repair of glial scars in rats with traumatic brain injury.

OBJECTIVE: To explore the underlying mechanism of acupuncture on nerve repair by investigating its effect on the differentiation of glial cells and the repair of glial scars. METHODS: Sprague-Dawley rats were randomly allocated to three groups: normal group, model group, and acupuncture group. Acupuncture was applied at Renzhong (GV26), Baihui (GV20), Fengfu (GV16), Yamen (GV15) and Hegu (LI4) within 12 h after TBI modeling with a frequency of one session per day for 4 weeks. Neurobehavioral assessment, hematoxylin and eosin staining, immunofluorescence detection, and magnetic resonance imaging scanning were performed on days 3, 7, 14, and 28 after modeling of traumatic brain injury (TBI). RESULTS: Acupuncture promoted the proliferation of glial cells and glial scars at an early stage but inhibited the proliferation of glial cells and glial scars at a late stage. Morphological observations and immunofluorescence histochemistry showed that the morphology of the perilesional cortex in the acupuncture group was improved and the number of neurons was increased when compared with the model group. The lesion size of ipsilateral brain parenchyma in the acupuncture group was smaller than in the model group on days 7, 14, and 28 ( < 0.05) after TBI modeling. CONCLUSIONS: Acupuncture might have a bidirectional regulatory effect on glial scar repair after TBI by promoting the proliferation of glial cells and glial scars to limit the injured area and relieve nerve injury during the early stages, and by inhibiting glial scar hyperplasia to benefit the regeneration and repair of neurons and axons and promote neurological function recovery during the later stages.

Clinical observation of HyperCVAD/HDMTX-L regimen as salvage treatment for patients with diffuse large B-cell lymphoma / 白血病·淋巴瘤

Objective To evaluate the efficacy and safety of HyperCVAD/HDMTX-L regimen as salvage treatment for patients with diffuse large B-cell lymphoma. Methods A retrospective study was made to analyze the efficacy and adverse reaction of HyperCVAD/HDMTX-L regimen as salvage treatment for 54 patients with diffuse large B-cell lymphoma. 27 cases were divided in CHOP class scheme ineffective group, 24 cases in recurrence group, HyperCVAD/MA regimen were as the control group. The efficacy in the treatment of 4 cycles, side effects of all cycles and 3-year progression free survival rates of the two regimens were compared. Results In CHOP class scheme ineffective group, efficiency rate of HyperCVAD/HDMTX-L was 59.3%(16/27), 3y PFS rate was 73.3%, efficiency rate of HyperCVAD/MA was 61.9 % (13/21), 3y PFS rate was 61.5%. There was no significant difference in efficiency and PFS rate between the two groups (P>0.05). In recurrence group, efficiency rate of HyperCVAD/HDMTX-L was 47.8 % (11/23), 3y PFS rate was 54.5 %, efficiency rate of HyperCVAD/MA was 45.5 % (10/22), 3y PFS rate was 50.0 %, there was no significant difference in efficiency and PFS rate between the two groups (P> 0.05). The incidence rates of nausea and vomiting, aleukocytosis, thrombocytopenia, hemorrhage associated with chemotherapy in HyperCVAD/HDMTX-L group were significantly lower than those in the control group (all P < 0.001). Conclusion HyperCVAD/HDMTX-L regimen maybe replace HyperCVAD/MA as the salvage treatment of diffuse large B-cell lymphoma.